Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1304-1307

  Rauw, Jennifer ^a   Ahmed, Shaheeda ^b   Petrella, Teresa ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Cardiac tamponade C14.280.155 ; Interferons D12.776.467.374.440 ; Melanoma C04.557.665.510 ; Pericardial effusion C14.280.695 ; Skin neoplams C04.588.805

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; AUTOIMMUNITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FLU LIKE SYNDROME; HEART TAMPONADE; HUMAN; LIMITED SCLERODERMA; LIVER TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PRIORITY JOURNAL; SYMPTOMATOLOGY; CHEMICALLY INDUCED DISORDER; METASTASIS; PROGNOSIS;

ADULT; CARDIAC TAMPONADE; FEMALE; HUMANS; INTERFERON-ALPHA; MELANOMA; PERICARDIAL EFFUSION; PROGNOSIS; RECOMBINANT PROTEINS;

EID: 84866271740     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9935-7     Document Type: Article

References (16)

1. Charles MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
2. Slijfer S, et al. Side effects of interferon-a treatment. Pharm World Sci. 2005;27(6):423-31.
3. Sonnenblick M, Rosin A. Cardiotoxicity of interferon A review of 44 cases. Chest. 1991;99(3):557-61.
4. Cohen M, Huberman M, Nesto R. Recombinant alpha 2 interferon- related cardiomyopathy. Am J Med. 1988;85:549-51.
5. Zimmerman S, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother. 1994;9(4):291-9.
6. Kruit WH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alphainterferon. An unexpected frequent complication. Cancer. 1994;74(10):2850-6.
7. Teragawa H, et al. Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. A case report. Jpn Heart J. 1996;31(1):137-42.
8. Sikole A, et al. Treatment of hepatitis C in hemodialysis patients with pegulated interferon alpha-2a as monotherapy. Ren Fail. 2007;29:961-1099.
9. Boonen A, Stockbrugger RW, van der Linden S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol. 1999;18:177-9.
10. Nikolaidis LA, et al. Hepatitis C virus-associated pericardial effusion and tamponade in liver transplant recipient. Can J Cardiol. 2004;20(7):719-21.
11. Vacher-Coponat H, et al. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha interferon. Nephrol Dial Transplant. 1994;14:2469-71.
12. Khakoo AY, Halushka MK, Rame JE. Reversible cardiomyopathy caused by administration of interferon a. Nat Clin Prac Cardiovascular Med. 2005;2(1):53-7.
13. Benjamini O, Kimhi O, Lishner M. Severe pleuropericarditis and cardiomyopathy induced by high dose interferon alpha-2b. IMAJ. 2007;9:486-7.
14. Hauschild A, et al. Practical guidelines for the management of interferon-a-2b Side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982-94.
15. Lin CT, et al. Myxedema associated with cardiac tamponade. Jpn Heart J. 2003;44(3):447-50.
16. Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354:709-18.